



HHS Public Access

Author manuscript

Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2024 February 09.

Published in final edited form as:

Paediatr Perinat Epidemiol. 2023 February ; 37(2): 165–178. doi:10.1111/ppe.12949.

The Pregnancy, Arsenic, and Immune Response (PAIR) Study in rural northern Bangladesh

Lindsay N. Avolio^{1,†}, Tyler J. S. Smith^{1,†}, Ana Navas-Acien², Kate Kruczynski¹, Nora Pisanic¹, Pranay R. Randad¹, Barbara Detrick³, Rebecca C. Fry⁴, Alexander van Geen⁵, Walter Goessler⁶, Ruth A. Karron⁷, Sabra L. Klein⁸, Elizabeth L. Ogburn⁹, Marsha Wills-Karp¹, Kelsey Alland⁷, Kaniz Ayesha¹⁰, Brian Dyer⁷, Md. Tanvir Islam¹⁰, Habibat A. Oguntade^{7,11}, Md. Hafizur Rahman¹⁰, Hasmot Ali¹⁰, Rezwanul Haque¹⁰, Saijuddin Shaikh¹⁰, Kerry J. Schulze⁷, A. K. M. Muraduzzaman¹², A. S. M. Alamgir¹², Meerjady Sabrina Flora¹², Keith P. West Jr.⁷, Alain B. Labrique⁷, Christopher D. Heaney^{1,7,13,*},
JiVitA Maternal and Child Health and Nutrition Research Project

¹Department of Environmental Health & Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

²Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY, USA

³Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

⁴Department of Environmental Sciences & Engineering, University of North Carolina at Chapel Hill Gillings School of Global Public Health, NC, USA

⁵Lamont-Doherty Earth Observatory, Columbia University, Palisades, NY, USA

⁶Institute of Chemistry - Analytical Chemistry, University of Graz, Graz, Austria

⁷Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

*Corresponding Author: Christopher D. Heaney, Department of Environmental Health & Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD USA, cheaney1@jhu.edu.

[†]LNA and TJSS contributed equally to this paper.

AUTHOR CONTRIBUTIONS

LNA and TJSS contributed equally to this paper. **LNA**: Writing – Original Draft, Data Curation, Methodology, Visualization; **TJSS**: Writing – Original Draft, Data Curation, Formal Analysis, Software, Visualization; **ANA**: Writing – Review & Editing, Conceptualization, Methodology, Supervision; **KK**: Data Curation, Resources; **NP**: Writing – Review & Editing, Conceptualization, Data Curation, Methodology, Project Administration; **PRR**: Methodology, Project Administration; **B Detrick**: Writing – Review & Editing, Conceptualization, Methodology; **RCF**: Writing – Review & Editing, Conceptualization, Methodology; **AvG**: Writing – Review & Editing, Investigation, Methodology; **WG**: Writing – Review & Editing, Investigation, Methodology; **RAK**: Writing – Review & Editing, Conceptualization, Methodology; **SLK**: Writing – Review & Editing, Conceptualization, Methodology; **ELO**: Methodology; **MWK**: Conceptualization, Methodology, Resources; **K Alland**: Writing – Review & Editing, Conceptualization, Methodology, Supervision; **K Ayesha**: Investigation, Supervision; **B Dyer**: Data Curation, Software; **MTI**: Investigation, Methodology; **HAO**: Investigation, Project Administration; **MHR**: Investigation, Methodology, Supervision; **HA**: Investigation, Methodology, Project Administration, Supervision; **RH**: Data Curation, Methodology, Supervision; **SS**: Conceptualization, Methodology, Project Administration, Supervision; **KJS**: Writing – Review & Editing, Conceptualization; **AKMM**: Investigation, Methodology; **ASMA**: Conceptualization, Methodology, Supervision; **MSF**: Methodology, Supervision; **KPW**: Conceptualization, Funding Acquisition, Supervision; **ABL**: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision; **CDH**: Writing – Review & Editing, Conceptualization, Data Curation, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision.

CONFLICT OF INTEREST

Authors report no conflicts of interest.

⁸Department of Molecular Microbiology & Immunology, Johns Hopkins University, Baltimore, MD, USA

⁹Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

¹⁰JiVitA Maternal and Child Health and Nutrition Research Project, Gaibandha, Bangladesh

¹¹Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, MN, USA

¹²Institute of Epidemiology, Disease Control, and Research, Dhaka, Bangladesh

¹³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Abstract

Background: Arsenic exposure and micronutrient deficiencies may alter immune reactivity to influenza vaccination in pregnant women, transplacental transfer of maternal antibodies to the foetus, and maternal and infant acute morbidity.

Objectives: The Pregnancy, Arsenic, and Immune Response (PAIR) Study was designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal and newborn immunity and acute morbidity following maternal seasonal influenza vaccination during pregnancy.

Population: The PAIR Study recruited pregnant women across a large rural study area in Gaibandha District, northern Bangladesh, 2018–2019.

Design: Prospective, longitudinal pregnancy and birth cohort.

Methods: We conducted home visits to enrol pregnant women in the late first or early second trimester (11 to 17 weeks of gestational age). Women received a quadrivalent seasonal inactivated influenza vaccine at enrolment. Follow-up included up to 13 visits between enrolment and three months postpartum. Arsenic was measured in drinking water and maternal urine. Micronutrient deficiencies were assessed using plasma biomarkers. Vaccine-specific antibody titres were measured in maternal and infant serum. Weekly telephone surveillance ascertained acute morbidity symptoms in women and infants.

Preliminary Results: We enrolled 784 pregnant women between October 2018 and March 2019. Of 784 women who enrolled, 736 (93.9%) delivered live births and 551 (70.3%) completed follow-up visits to three months postpartum. Arsenic was detected ($> 0.02 \mu\text{g/L}$) in 99.7% of water specimens collected from participants at enrolment. The medians (interquartile ranges) of water and urinary arsenic at enrolment were 5.1 (0.5, 25.1) $\mu\text{g/L}$ and 33.1 (19.6, 56.5) $\mu\text{g/L}$, respectively. Water and urinary arsenic were strongly correlated (Spearman's $\rho=0.72$) among women with water arsenic \geq median but weakly correlated ($\rho=0.17$) among women with water arsenic $<$ median.

Conclusions: The PAIR Study is well positioned to examine the effects of low-moderate arsenic exposure and micronutrient deficiencies on immune outcomes in women and infants.

Registration: [NCT03930017](#)

Keywords

Arsenic; Immunogenicity; Vaccine; Influenza; Micronutrients; Pregnancy; Prenatal Exposure
Delayed Effects

BACKGROUND

Arsenic exposure is a major threat to global health. About 140 million people worldwide are exposed to drinking water arsenic exceeding the World Health Organization's (WHO's) guideline value of 10 µg/L.¹ Arsenic causes bladder, lung, and skin cancers² and has been associated with cardiovascular disease, diabetes mellitus, and the metabolic syndrome.^{3,4} Over the past decade, multiple studies have found that arsenic was associated with altered cellular⁵ and humoral immune responses^{6–8} and increased risk of infection, acute morbidity, and related mortality.^{9–12} Of particular concern is immunotoxicity following exposure during pregnancy and early life.¹³ However, while exposure *in utero* has been associated with reduced pathogen-specific antibody responses to some childhood vaccinations^{6–8} and increased risk of respiratory and gastrointestinal morbidities in children,^{14–21} less is known about arsenic and the immune response in pregnant women and newborns during the first months of life. In addition, arsenic methylation facilitated by one-carbon metabolism appears to modify arsenic toxicity for certain chronic disease outcomes.²² Arsenic methylation typically increases during pregnancy.^{23–25} However, few studies of arsenic immunotoxicity have evaluated potential effect measure modification by micronutrient deficiencies that influence arsenic methylation in pregnant women.

The WHO recommends seasonal influenza vaccination at any stage of pregnancy to protect pregnant women and infants <6 months of age,²⁶ who benefit from maternal antibodies transferred across the placenta.^{27–29} Since the risk of severe illness from infection by influenza virus is higher in pregnant women and infants,^{30,31} expanding maternal vaccination against influenza is imperative. If arsenic reduces the maternal antibody response to influenza vaccine or transplacental transfer of maternal antibodies to the foetus, however, additional interventions may be needed. Yet relations among arsenic exposure, micronutrient deficiencies, antibody responses to influenza vaccination in pregnant women, transplacental transfer of maternal antibodies, and influenza-like illness (ILI) and other acute morbidities remain poorly understood.^{32,33}

To better understand the influence of arsenic on immune responses in pregnant women and newborns, we established the Pregnancy, Arsenic, and Immune Response (PAIR) Study, a longitudinal pregnancy and birth cohort, in rural northern Bangladesh. The PAIR Study was designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal and newborn immunity and acute morbidity following maternal seasonal influenza vaccination during pregnancy. We hypothesized that arsenic exposure and one-carbon metabolism micronutrient deficiencies may alter maternal and newborn influenza antibody titre and avidity, measures of systemic immune responses, and respiratory and other acute morbidity outcomes among pregnant women and newborns.

METHODS

Study Area

The PAIR Study is based at the JiVitA Maternal and Child Health and Nutrition Research Project (JiVitA) in rural northern Bangladesh. Approximately 45 million people in Bangladesh are exposed to arsenic concentrations in drinking water $>10 \mu\text{g/L}$ (the WHO guideline value) and, of these, approximately 20 million people are exposed to arsenic concentrations $>50 \mu\text{g/L}$ (the Bangladesh national standard).³⁴ For nearly two decades, JiVitA has been one of the largest research project sites in South Asia, covering ~650,000 people over 450 km² of Bangladesh's Gaibandha and Rangpur Districts (Figure 1).³⁵ JiVitA is an extensive field organization that has conducted large trials of food and micronutrient supplements among pregnant women and children.^{36–38} A case-control study nested in a previous JiVitA micronutrient supplement trial found that urinary arsenic was associated with seroconversion to hepatitis E virus between the first trimester and three months postpartum among pregnant women in the study area.⁹ The PAIR Study builds on this work.

Enrolment and Vaccination

From July 2018 to February 2019, we conducted pregnancy surveillance to identify eligible pregnant women in the study area. A married woman of reproductive age (13–45 years) was eligible for the PAIR Study if she was pregnant and 13–14 weeks of gestational age (GW) (later 13–16 GW; see below), had no pre-existing immunodeficiency or chronic infection, had no previous or current use of immune-altering drugs or therapies (*e.g.*, steroids), and had not yet received an influenza vaccine for the 2018–19 influenza season.

The full JiVitA study area is divided into 566 sectors of ~150–300 households each (Figure 1). For the PAIR Study, surveillance began in 175 sectors closest to clinical centres where vaccination and biospecimen collections, including venepuncture, could be safely performed and samples could be uniformly processed (“PAIR Original Area” in Figure 1). We estimated *a priori* that enrolling 850 pregnant women in 13–14 GW would yield a target sample size of 400 mother-infant pairs retained in the study to three months postpartum. We also determined *a priori* that enrolment should end by March 2019 so that pregnancies would be limited to a single influenza season and follow-up visits at 28 days post-vaccination would occur before the Ramadan fast (5 May to 3 June, 2019). In November 2018, seeking to achieve the target enrolment in this time window, we enlarged the study area by 163 sectors (“PAIR Extension Areas” in Figure 1) and expanded eligibility criteria to 13–16 GW.

A total of 66,056 married women of reproductive age living in the original or extension areas were identified by an earlier census or during pregnancy surveillance (Figure 2). During surveillance, a female community health research worker (CHRW) visited each household every four weeks and asked each married woman of reproductive age about the date of her last menstrual period. If the date was >30 days prior to the visit, the woman was offered a urine pregnancy test. A positive test indicated that the woman was pregnant. Gestational age was calculated from the date of her last menstrual period. We completed at least one surveillance visit to 46,776 women to identify 2,616 pregnant women (Figure 2). Of these, 845 women were eligible and consented to enrolment, and

784 women enrolled in the PAIR Study between October 2018 and March 2019 (Figure 2). For logistical reasons inherent to conducting visits over a large rural area in a low-income country, we ultimately enrolled 8 women in GW 11–12 (1.0%), 775 women in GW 13–16 (98.9%), and 1 woman in GW 17 (0.1%). At enrolment, all women received a quadrivalent seasonal inactivated influenza vaccine (VaxigripTetra, Sanofi Pasteur, Lyon, France), which was recommended by the WHO for the 2018–19 Northern Hemisphere influenza season. The vaccine contained four inactivated influenza virus strains: A/Michigan/2015 (H1N1), A/Singapore/2016 (H3N2), B/Maryland/2016, and B/Phuket/2013.³⁹ All vaccines were maintained under a cold-chain protocol, carefully temperature-monitored, and administered by trained nurses working under the supervision of a JiVitA physician.

Sociodemographic characteristics, including age, education, socioeconomic status, household size (number of people), and house size (number of rooms excluding the kitchen and storerooms), were similar between pregnant women who enrolled in the PAIR Study (n=784) and pregnant women in the study area who did not enrol (n=1,519, after excluding women who were missing sociodemographic information [n=313]) (Table 1). Women who enrolled tended to be younger and have higher socioeconomic status, but these differences were small (Table 1). Socioeconomic status was assessed by living standards index, which was generated by a principal components analysis of household assets and home construction materials and validated in a previous JiVitA study.⁴⁰ The use of tube wells to obtain groundwater for drinking and cooking was nearly universal among enrollees (99.4%) and non-enrolees (99.8%) alike (Table 1).

Study Visits

We completed up to 13 in-person visits to implement questionnaires and collect biological and environmental specimens, beginning at enrolment and continuing to three months postpartum, for a follow-up period of roughly 10 months, depending on the timing and duration of each pregnancy (Tables 2 and 3). These included up to eight visits to the woman during pregnancy and up to five visits to mother-infant pairs after live birth. At three visits (enrolment and vaccination, 28 days post-vaccination, and three months postpartum), the CHRW brought participants (the mother in pregnancy, the mother-infant pair after live birth) to a local clinical centre for detailed questionnaire and biospecimen collection. To minimize burden on mothers and infants in the neonatal period, home visits were conducted shortly after any live birth and again <1 month postpartum for further questionnaire and biospecimen collection. Of 784 women who enrolled, 744 (94.9%) completed the 28-day post-vaccination visit, 598 (76.3%) completed a visit <1 month postpartum, and 551 (70.3%) completed the three-month postpartum visit (Table 4). In total, 736 (93.9%) enrolled women had 750 live births, including 722 singletons and 28 twins. Age, gestational age at enrolment, parity, education, living standards index, household size (number of people), house size (number of rooms), height, body mass index at enrolment, and urinary arsenic at enrolment were similar among the women who enrolled and the subset of women who completed follow-up at three months postpartum (Table 4).

In partnership with the Institute of Epidemiology, Disease Control, and Research (IEDCR), a unit of the Bangladesh Ministry of Health and Family Welfare, we conducted weekly

telephone surveillance to ascertain acute morbidities in women (enrolment to three months postpartum) and infants (birth to three months postpartum). In women, we ascertained high fever with cough, high fever with sore throat, diarrhoea, vomiting, and abdominal pain. If a woman reported high fever with cough or sore throat, she was asked further if she had congestion, headache, or chills at the same time. In infants, we ascertained high fever with cough, diarrhoea, and vomiting. If a woman reported that her infant had high fever with cough, she was asked further if the infant had congestion or shortness of breath at the same time. Of 784 women enrolled in the PAIR Study and 750 infants born to them, 743 women (94.8%) and 617 infants (82.3%) participated in the surveillance.

Environmental Specimens

We collected a water specimen from the tube well that each participant indicated was her primary source of drinking water before each centre visit and at the home visit conducted <1 month postpartum (Table 2). Just prior to collection, the well was flushed for approximately five minutes. Specimens were collected into conical vials certified by the manufacturer as trace-metal free (<1 µg/L for 20 metals, including As), and transported to the local JiVitA lab at 4–10°C. Specimens were aliquoted and stored at -20°C prior to analysis. Tube well water specimens were analysed for total arsenic (wAs) and other elements (Al, Ba, Br, Ca, Cd, Cu, Fe, K, Mg, Mn, Mo, Na, P, Pb, S, Sb, Si, Sr, U, V, W, Zn) at the Lamont-Doherty Earth Observatory in Palisades, NY using inductively coupled plasma mass spectrometry.⁴¹ Empty trace metal-free conical vials and aliquot tubes were assessed as blanks. To determine the limit of detection (LOD) for each element, we used the highest LOD across all batches. For wAs, this was 0.02 µg/L.

Biological Specimens

Up to 22 mL of venous blood were collected from mothers at each of the three centre visits: enrolment/vaccination, 28 days post-vaccination, and three months postpartum (Table 2). Up to 1 mL of capillary blood was collected from infants by heel stick during the centre visit at three months postpartum (Table 3). At the home visit <1 month postpartum, blood was collected from mothers and infants using the methods described for the centre visits. After blood collection, each participant received a light snack (*e.g.*, a glucose packet). Blood specimens were transported in temperature-controlled and -monitored coolers to a JiVitA laboratory. Laboratory technicians processed maternal blood to serum, plasma, and peripheral blood mononuclear cells (PBMCs), and processed infant blood to serum, on the day of collection. Serum and plasma were frozen and maintained at -80°C. PBMCs were cryopreserved following established protocols.⁴² Serum and plasma were shipped on dry ice, and PBMCs were shipped in vapor phase liquid nitrogen canisters, to the Johns Hopkins University in Baltimore, Maryland. Maternal and infant sera were tested for antibody for the influenza vaccine antigens by hemagglutination-inhibition (HAI) assay at Sanofi Pasteur in Swiftwater, Pennsylvania.⁴³ Transplacental antibody transfer will be assessed by infant-to-maternal HAI antibody titre ratios measured in serum collected <1 month postpartum. We also will determine avidity of IgG antibodies specific to the influenza vaccine antigens; serum cytokine and chemokine concentrations as measures of immune function; immune cell population characterization; and T-cell stimulation assays using the influenza vaccine antigens. We will assess plasma biomarkers relevant to one-carbon metabolism, infection,

and inflammation. Assays completed to date include plasma folate, homocysteine, vitamin B12, ferritin, and alpha(1)-acid glycoprotein (AGP). Planned future assays include plasma albumin, vitamin D, and zinc.

Urine was collected from all mothers at the three centre visits and during the home visit <1 month postpartum, and from a subset of mothers (n=468) during a home visit in late pregnancy (Table 2). Mothers were asked to provide a urine specimen in a collection cup. A CHRW immediately transferred the specimen to a container certified by the manufacturer as trace-metal free (<1 µg/L for 20 metals, including As) and the specimens were transported to the JiVitA laboratory. Urine specimens were aliquoted and stored at -20°C prior to analysis. Urinary elements (Al, Ba, Br, Ca, Cd, Cs, Cu, Fe, K, Li, Mg, Mn, Mo, Na, P, Pb, Rb, S, Sb, Se, Si, Sr, U, V, W, Zn) were measured at the Institute of Chemistry - Analytical Chemistry at the University of Graz in Graz, Austria using inductively coupled plasma tandem mass spectrometry (ICP-MS/MS). Urinary arsenic was speciated (arsenite, arsenate, monomethylarsonic acid (MMA), dimethylarsinic acid (DMA), and arsenobetaine and other cations) by high performance liquid chromatography (HPLC) with ICP-MS/MS as described by Scheer et al.⁴⁴ Empty trace-metal free containers and aliquot tubes were assessed as blanks. The LODs for arsenic species were 0.05 µg/L. To assess arsenic exposure, we summed urinary inorganic arsenic (the sum of arsenite and arsenate; iAs), MMA, and DMA (µAs).⁴⁵ To assess arsenic metabolism, we calculated proportions of urinary iAs, MMA, and DMA, relative to µAs, and reported them as iAs%, MMA%, and DMA%.²² All urinary concentrations were corrected for specific gravity measured by refractometric determination of total solids.

We collected oral fluid, which includes saliva, oral mucosal transudate from the capillary bed, and crevicular fluid, from mothers at each centre visit, the home visit after birth, and additional monthly home visits, and from infants in all visits beginning at one month postpartum (Tables 2 and 3). Crevicular fluid, which flows between the gums and the teeth, is rich in antibodies and reflects the IgG profile of the serum. Oral fluid was collected by brushing the gum line with an oral-mucosal transudate collection swab.⁴⁶⁻⁴⁸ Microsphere magnetic bead-based assays will be applied to measure IgG and IgA responses specific to the influenza vaccine strains as well as a variety of endemic respiratory and gastrointestinal pathogens.^{46,47,49}

If a mother reported influenza-like illness (ILI) in herself or her infant during weekly surveillance, a CHRW aimed to conduct a home visit and collect a nasal swab within 24 hours of the call (Tables 2 and 3). ILI was defined as high fever with cough or sore throat in women and high fever with cough in infants.⁵⁰ Severity was determined by calculating the sum of acute morbidity symptoms reported during surveillance. Given limited capacity, women or infants with the highest sum score were prioritized for the collection of a nasal swab. After collection by a CHRW, swabs were placed in universal transport medium intended for the preservation of viruses (Puritan UniTranz-RT, Guilford, ME, USA). Samples were transported to the local JiVitA lab and stored at -80°C. Nasal swabs were periodically batch-transported to IEDCR in Dhaka, Bangladesh, in liquid nitrogen, where RNA will be extracted and tested by RT-qPCR for influenza A and B virus, including sub-types, according to WHO protocols to assess laboratory-confirmed ILI.⁵¹

Anthropometry

Maternal weight (kg), height (cm), mid-upper arm circumference (MUAC) (cm), and triceps and subscapular skinfolds (mm) were measured at enrolment/vaccination and three months postpartum (Table 2).^{37,52,53} Maternal weight was also measured at 28 days post-vaccination, late pregnancy, and one month postpartum. Maternal MUAC was also measured at late pregnancy and one month postpartum. Infant weight, MUAC, chest circumference, head circumference, and length were recorded at the birth assessment visit (Table 3).^{37,52,53} Infant growth was monitored by repeating these measurements at one and three months postpartum.

Vitals

Blood pressure, haemoglobin, and body temperature of mothers were measured by a local nurse each time a mother had blood drawn (Table 2). Systolic and diastolic blood pressure were measured twice, in the left arm, with the woman in a relaxed and seated position using a WelchAllyn DuraShock DS66 Trigger Aneroid Sphygmomanometer (Skaneateles Falls, New York, USA). Haemoglobin was measured in capillary blood by real-time assay using a HemoCue Hb 301 analyser (Ängelholm, Sweden). Body temperature of infants was measured at the birth assessment and three months postpartum, and haemoglobin was measured at three months postpartum by a local nurse (Table 3). Blood type was determined using anti-A, anti-B, and anti-D blood grouping reagents (Cromatest, LiNEAR, Montgat, Spain). Vitals were recorded and provided to the mother after each collection. Pregnant women and infants who were severely anaemic (haemoglobin <7 g/dL)⁵⁴ were given iron tablets and iron syrup, respectively, consistent with the study protocol and as approved by the IRB.

Questionnaires

Questionnaires conducted at multiple visits between enrolment/vaccination and three months postpartum covered a variety of topics (Table 2), including questions related to the intentionality of pregnancy, seven- and thirty-day morbidity including influenza-like illness, seven-day food frequency, mental health, seven-day strenuous work activity, six-month pesticide storage and use, poultry farming and exposures, handwashing practices, tobacco use and smoke exposure, medical and vaccination history, household food security, and more. Topics related to potential sources of arsenic exposure included drinking water and rice consumption, chewing tobacco use, and husband's smoking. Additional questionnaires asked about the birth and delivery of infants, including characteristics of labour and delivery, micronutrient supplement consumption, and health crisis events. Answers to questionnaires for infants were most often provided by the mother and included morbidity, breast feeding practices, early feeding practices, infant injury and bleeding, immunization and supplementation, and hospitalization history and medication use (Table 3).

Ethics Approval and Participation Incentives

This study was approved by the institutional review boards of the Johns Hopkins Bloomberg School of Public Health (00008247) and the Institute of Epidemiology, Disease Control and Research (IEDCR/IRB/2017/07). All participants gave informed consent prior to enrolment.

All women received several participation incentives. These included the seasonal influenza vaccination, dietary counselling, antenatal care education, and a clean birthing kit (many births in the study area occur at home). As described above, we tested haemoglobin and provided severely anaemic participants with iron supplements. In women who reported severe morbidity, we provided a referral for treatment and covered the cost of transportation to receive treatment. Finally, women who completed follow-up at three months post-partum received a sari.

PRELIMINARY RESULTS

Arsenic was detected ($> 0.02 \mu\text{g/L}$) in 99.7% of water specimens collected from participants' tube wells on the day of enrolment. The median (IQR) of wAs was 5.1 (0.5, 25.1) $\mu\text{g/L}$ (Figure 3) with 39.5% of samples above the WHO guideline value of 10 $\mu\text{g/L}$ and 13.4% above the Bangladesh national standard of 50 $\mu\text{g/L}$. wAs appears to be lower in the study area than in other regions of Bangladesh where epidemiologic studies have been conducted.^{55,56} Urinary iAs, MMA, and DMA were LOD in all specimens collected at enrolment. The median (IQR) of their sum, μAs , was 33.1 (19.6, 56.5) $\mu\text{g/L}$ (Figure 3). Urinary arsenobetaine (and other unretained arsenic species) levels were low (median: 0.8 $\mu\text{g/L}$; IQR: 0.4, 1.7 $\mu\text{g/L}$), suggesting low exposure to organic arsenic from seafood in the population.⁵⁷ Overall, μAs was strongly correlated with wAs (Spearman's $\rho=0.69$) (Figure 4). The correlation was slightly stronger in participants with wAs \geq median (Spearman's $\rho=0.72$) but weak in participants with wAs $<$ median (Spearman's $\rho=0.17$) (Figure 4). This suggests that, at lower concentrations of wAs, other sources of arsenic (e.g., other tube wells, rice) contribute relatively more to exposure.⁵⁸ μAs and wAs will provide complementary approaches to exposure assessment. μAs integrates exposures from multiple sources, including drinking water and diet, but has a short biological half-life and may over- or under-estimate long-term exposure.⁴⁵ By contrast, wAs reflects a single source of exposure but is more stable over time. Future work will characterize exposure to arsenic and other metals and associations with health outcomes, including maternal antibody response to influenza vaccination, transplacental transfer of maternal antibodies, and respiratory morbidity, as well as interactions between arsenic exposure and micronutrient deficiencies in these outcomes.

COMMENT

Strengths of the Study

Strengths of the PAIR Study include a large, representative sample of pregnant women and infants in rural northern Bangladesh. The women received the same seasonal influenza vaccine at approximately the same time during pregnancy and during the same influenza season. This design will enable us to assess whether arsenic exposure is associated with antibody responses to seasonal influenza vaccination in pregnant women or transplacental transfer of maternal antibodies to the foetus while avoiding potential confounders related to stage of pregnancy and annual variability in influenza viruses. Because wAs appears to be lower in the PAIR Study than in other epidemiologic studies in Bangladesh, we can assess whether low-moderate arsenic exposure is associated with relevant maternal and

infant outcomes. Biological and environmental specimens provide objective measures of arsenic exposure and immune and respiratory and other acute morbidity outcomes. Weekly telephone surveillance provides ascertainment of ILI symptoms and real-time PCR testing of anterior nasal swabs in ILI-symptomatic persons provides time-resolved information on maternal and infant laboratory-confirmed influenza A/B infection.

Limitations of the Data

Limitations include occasional delays in study visits. While JiVitA possesses an extensive field organization, logistical barriers to conducting frequent home visits over a large rural study area prevented some study visits from occurring as scheduled. Additionally, it was not logistically feasible to collect umbilical cord blood specimens to assess transplacental transfer of maternal antibodies. However, infant-to-maternal HAI antibody titre ratios measured in serum collected <1 month postpartum should provide a reasonable alternative because neonates demonstrate only a limited adaptive immune response that would allow them to generate IgG antibodies independently,⁵⁹ and the maternal antibodies received through breast milk are IgA.

Collaboration

The PAIR Study was designed and conducted through collaboration among investigators at the Johns Hopkins University, Columbia University, and the University of North Carolina at Chapel Hill in the United States; the University of Graz in Austria; and the JiVitA Maternal and Child Health and Nutrition Research Project in Bangladesh. We welcome further collaboration. Please contact the principal investigators, Christopher D. Heaney (cheaney1@jhu.edu) and Alain B. Labrique (alabriq1@jhu.edu), for more information.

CONCLUSION

The PAIR Study enrolled a large, representative sample of pregnant women in the late first and early second trimester in rural northern Bangladesh. We have obtained high-quality measurements of arsenic exposure, key micronutrients, and immune-related outcomes in pregnant women and infants. These data will provide unique opportunities to examine effects of low-moderate arsenic exposure and micronutrient deficiencies on immunity in pregnancy and early life. We are open to collaborations with investigators working on these issues.

FUNDING INFORMATION

The PAIR study was supported by the National Institute of Environmental Health Sciences (NIEHS; award number R01ES026973) and by an unrestricted grant from Sanofi Pasteur (award number N/A), Lyon, France, which also provided the study vaccine and vaccine antibody testing. PAIR also benefited from common JiVitA infrastructure and staff supported by the UBS Optimus Foundation (award number N/A) and the Bill & Melinda Gates Foundation (award number N/A). LNA was supported by a grant from the U.S. Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health to the Johns Hopkins Education and Research Center for Occupational Safety and Health (T42 OH0008428) and the National Science Foundation Graduate Research Fellowship (DGE-1746891). TJSS was supported by NIEHS (T32ES007141).

REFERENCES

1. Ravenscroft P, Brammer H, Richards K. Arsenic Pollution: A Global Synthesis West Sussex: Wiley-Blackwell; 2009.
2. IARC (International Agency for Research on Cancer). Arsenic and Arsenic Compounds Geneva: World Health Organization; 2012.
3. Moon KA, Oberoi S, Barchowsky A, Chen Y, Guallar E, Nachman KE, et al. A dose-response meta-analysis of chronic arsenic exposure and incident cardiovascular disease. *International Journal of Epidemiology* 2017;46:1924–1939. [PubMed: 29040626]
4. Navas-Acien A, Spratlen MJ, Abuawad A, LoIacono NJ, Bozack AK, Gamble M v. Early-Life Arsenic Exposure, Nutritional Status, and Adult Diabetes Risk. *Current Diabetes Reports* 2019;19:147–154. [PubMed: 31758285]
5. Ahmed S, Moore SE, Kippler M, Gardner R, Hawlader MDH, Wagatsuma Y, et al. Arsenic exposure and cell-mediated immunity in pre-school children in rural Bangladesh. *Toxicological Sciences* 2014;141:166–175. [PubMed: 24924402]
6. Welch BM, Branscum A, Geldhof GJ, Ahmed SM, Hystad P, Smit E, et al. Evaluating the effects between metal mixtures and serum vaccine antibody concentrations in children: A prospective birth cohort study. *Environmental Health* 2020;19:41. [PubMed: 32276596]
7. Welch BM, Branscum A, Ahmed SM, Hystad P, Smit E, Afroz S, et al. Arsenic exposure and serum antibody concentrations to diphtheria and tetanus toxoid in children at age 5: A prospective birth cohort in Bangladesh. *Environment International* 2019;127:810–818. [PubMed: 31051324]
8. Raqib R, Ahmed S, bin Ahsan K, Kippler M, Akhtar E, Roy AK, et al. Humoral immunity in arsenic-exposed children in rural Bangladesh: Total immunoglobulins and vaccine-specific antibodies. *Environmental Health Perspectives* 2017;125:067006. [PubMed: 28657894]
9. Heaney CD, Kmush B, Navas-Acien A, Francesconi K, Gössler W, Schulze K, et al. Arsenic exposure and hepatitis E virus infection during pregnancy. *Environmental Research* 2015;142:273–280. [PubMed: 26186135]
10. Kile ML, Rodrigues EG, Mazumdar M, Dobson CB, Diao N, Golam M, et al. A prospective cohort study of the association between drinking water arsenic exposure and self-reported maternal health symptoms during pregnancy in Bangladesh. *Environmental Health* 2014;13.
11. Smith AH, Marshall G, Yuan Y, Liaw J, Ferreccio C, Steinmaus C. Evidence from Chile that arsenic in drinking water may increase mortality from pulmonary tuberculosis. *American Journal of Epidemiology* 2011;173:414–420. [PubMed: 21190988]
12. Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, von Ehrenstein O, et al. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. *Environmental Health Perspectives* 2006;114:1293–1296. [PubMed: 16882542]
13. Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection During Pregnancy and Early Life. *Current Environmental Health Reports* 2017;4:229–243. [PubMed: 28488132]
14. Islam LN, Nabi AHMN, Rahman MM, Shamim M, Zahid H. Association of respiratory complications and elevated serum immunoglobulins with drinking water arsenic toxicity in human. *Journal of Environmental Science and Health, Part A. Toxic/Hazardous Substances and Environmental Engineering* 2007;42:1807–1814. [PubMed: 17952781]
15. Farzan SF, Korrick S, Li Z, Enelow R, Gandolfi AJ, Madan J, et al. In utero arsenic exposure and infant infection in a United States cohort: a prospective study. *Environmental Research* 2013;126:24–30. [PubMed: 23769261]
16. Farzan SF, Li Z, Korrick SA, Spiegelman D, Enelow R, Nadeau K, et al. Infant Infections and Respiratory Symptoms in Relation to in Utero Arsenic Exposure in a U.S. Cohort. *Environmental Health Perspectives* 2016;124:840–847. [PubMed: 26359651]
17. Ahmed SM, Branscum A, Welch BM, Megowan M, Bethel JW, Odden MC, et al. A prospective cohort study of in utero and early childhood arsenic exposure and infectious disease in 4- to 5-year-old Bangladeshi children. *Environmental Epidemiology* 2020;4:e086. [PubMed: 32656486]

18. George CM, Brooks WA, Graziano JH, Nonyane BAS, Hossain L, Goswami D, et al. Arsenic exposure is associated with pediatric pneumonia in rural Bangladesh: a case control study. *Environmental Health* 2015;14:83. [PubMed: 26497043]
19. Rahman A, Vahter M, Ekström E-C, Persson L-Å. Arsenic exposure in pregnancy increases the risk of lower respiratory tract infection and diarrhea during infancy in Bangladesh. *Environmental Health Perspectives* 2011;119:719–724. [PubMed: 21147604]
20. Raqib R, Ahmed S, Sultana R, Wagatsuma Y, Mondal D, Hoque AMW, et al. Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh. *Toxicology Letters* 2009;185:197–202. [PubMed: 19167470]
21. Smith AH, Yunus M, Khan AF, Ercumen A, Yuan Y, Smith MH, et al. Chronic respiratory symptoms in children following in utero and early life exposure to arsenic in drinking water in Bangladesh. *International Journal of Epidemiology* 2013;42:1077–1086. [PubMed: 24062297]
22. Kuo CC, Moon KA, Wang SL, Silbergeld E, Navas-Acien A. The association of arsenic metabolism with cancer, cardiovascular disease, and diabetes: A systematic review of the epidemiological evidence. *Environmental Health Perspectives* 2017;125.
23. Hopenhayn C, Huang B, Christian J, Peralta C, Ferreccio C, Atallah R, et al. Profile of urinary arsenic metabolites during pregnancy. *Environmental Health Perspectives* 2003;111:1888–1891. [PubMed: 14644662]
24. Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. Exposure to inorganic arsenic metabolites during early human development. *Toxicological Sciences* 1998;44:185–190. [PubMed: 9742656]
25. Vahter M Effects of arsenic on maternal and fetal health. *Annual Review of Nutrition* 2009;29:381–399.
26. World Health Organization. WHO position paper on influenza vaccines - November 2012. *Weekly Epidemiological Record* 2012;87:461–476. [PubMed: 23210147]
27. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. *New England Journal of Medicine* 2008;359:1555–1564. [PubMed: 18799552]
28. Reuman PD, Ayoub EM, Small PA. Effect of passive maternal antibody on influenza illness in children: a prospective study of influenza A in mother-infant pairs. *Pediatric Infectious Disease Journal* 1987;6:398–403. [PubMed: 3588113]
29. Puck JM, Glezen WP, Frank AL, Six HR. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. *Journal of Infectious Disease* 1980;142:844–849.
30. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. *Pediatric Infectious Disease Journal* 1997;16:1065–1068. [PubMed: 9384341]
31. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. *American Journal of Epidemiology* 1998;148:1094–1102. [PubMed: 9850132]
32. Ser PH, Banu B, Jebunnesa F, Fatema K, Rosy N, Yasmin R, et al. Arsenic exposure increases maternal but not cord serum IgG in Bangladesh. *Pediatrics International* 2015;57:119–125. [PubMed: 24862852]
33. Attreed SE, Navas-Acien A, Heaney CD. Arsenic and Immune Response to Infection During Pregnancy and Early Life. *Current Environmental Health Reports* 2017;4:229–243. [PubMed: 28488132]
34. Flanagan S v Johnston RB, Zheng Y. Arsenic in tube well water in Bangladesh: health and economic impacts and implications for arsenic mitigation. *Bulletin of the World Health Organization* 2012;90:839–846. [PubMed: 23226896]
35. Ali H, Hamadani J, Mehra S, Tofail F, Hasan MI, Shaikh S, et al. Effect of maternal antenatal and newborn supplementation with Vitamin A on cognitive development of school-aged children in rural Bangladesh: A follow-up of a placebo-controlled, randomized trial. *American Journal of Clinical Nutrition* 2017;106:77–87. [PubMed: 28490513]
36. Klemm RDW, Labrique AB, Christian P, Rashid M, Shamim AA, Katz J, et al. Newborn Vitamin A Supplementation Reduced Infant Mortality in Rural Bangladesh. *Pediatrics* 2008;122:e242–e250. [PubMed: 18595969]

37. West KP Jr, Christian P, Labrique AB, Rashid M, Shamim AA, Klemm RDW, et al. Effects of vitamin A or beta carotene supplementation on pregnancy-related mortality and infant mortality in rural Bangladesh: A cluster randomized trial. *JAMA* 2011;305:1986–1995. [PubMed: 21586714]
38. West KP Jr, Shamim AA, Mehra S, Labrique AB, Ali H, Shaikh S, et al. Effect of Maternal Multiple Micronutrient vs Iron-Folic Acid Supplementation on Infant Mortality and Adverse Birth Outcomes in Rural Bangladesh: The JiVitA-3 Randomized Trial. *JAMA* 2014;312:2649–2658. [PubMed: 25536256]
39. Serradell L, Wagué S, Moureau A, Nissilä M, Chabanon A-L. Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season. *Human Vaccines & Immunotherapeutics* 2021;17:1205–1210. [PubMed: 32966139]
40. Gunnsteinnsson S, Labrique AB, West KP, Christian P, Mehra S, Shamim AA, et al. Constructing indices of rural living standards in Northwestern Bangladesh. *Journal of Health, Population and Nutrition* 2010;28:509–519. [PubMed: 20941903]
41. Cheng Z, Zheng Y, Mortlock R, van Geen A. Rapid multi-element analysis of groundwater by high-resolution inductively coupled plasma mass spectrometry. *Analytical and Bioanalytical Chemistry* 2004;379:512–518. [PubMed: 15098084]
42. Weinberg A Cryopreservation of Peripheral Blood Mononuclear Cells. In: *Manual of Molecular and Clinical Laboratory Immunology*. Editors: Detrick B, Schmitz JL, Hamilton RG: 8th ed. Washington, DC: ASM Press, 2016; pp. 263–268.
43. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. *Journal of Infectious Disease* 2011;204:1879–1885.
44. Scheer J, Findenig S, Goessler W, Francesconi KA, Howard B, Umans JG, et al. Arsenic species and selected metals in human urine: validation of HPLC/ICPMS and ICPMS procedures for a long-term population-based epidemiological study. *Analytical Methods* 2012;4:406–413. [PubMed: 22685491]
45. National Research Council. *Arsenic in Drinking Water* Washington, DC: National Academies Press; 1999.
46. McKie A, Vyse A, Maple C. Novel methods for the detection of microbial antibodies in oral fluid. *Lancet Infectious Diseases* 2002;2:18–24. [PubMed: 11892490]
47. Randad PR, Hayford K, Baldwin R, Avolio L, Pisanic N, Moss WJ, et al. The Utility of Antibodies in Saliva to Measure Pathogen Exposure and Infection. In: *Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and Applications* Editors: Granger Douglas A., Taylor Marcus K.: 1st ed. Cham, Switzerland: Springer Nature, 2020; pp. 287–319.
48. Brandtzaeg PER. Do salivary antibodies reliably reflect both mucosal and systemic immunity? *Annals of the New York Academy of Sciences* 2007;1098:288–311. [PubMed: 17435136]
49. Randad PR, Pisanic N, Kruczynski K, Manabe YC, Thomas D, Pekosz A, et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. *Journal of Clinical Microbiology* 2020;59:e02204. [PubMed: 33067270]
50. Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, et al. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. *Bulletin of the World Health Organization* 2018;96:122–128. [PubMed: 29403115]
51. World Health Organization (WHO). Information for the Molecular Detection of Influenza Viruses https://www.who.int/influenza/gisrs_laboratory/WHO_information_for_the_molecular_detection_of_influenza_viruses_20171023_Final.pdf.
52. West KP Jr, Shamim AA, Labrique AB, Ali H, Shaikh S, Mehra S, et al. Efficacy of Antenatal Multiple Micronutrient (MM) vs Iron-Folic Acid (IFA) Supplementation in Improving Gestational and Postnatal Viability in Rural Bangladesh: The JiVitA-3 Trial. *FASEB Journal* 2013;27:358.6–358.6.
53. Kim JM, Labrique A, West KP, Rashid M, Shamim AA, Ali H, et al. Maternal morbidity in early pregnancy in rural northern Bangladesh. *International Journal of Gynecology & Obstetrics* 2012;119:227–233. [PubMed: 23040408]
54. World Health Organization (WHO). *Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity* Geneva, Switzerland; 2011.

55. Ahsan H, Chen Y, Parvez F, Argos M, Hussain AI, Momotaj H, et al. Health Effects of Arsenic Longitudinal Study (HEALS): description of a multidisciplinary epidemiologic investigation. *Journal of Exposure Science and Environmental Epidemiology* 2006;16:191–205. [PubMed: 16160703]
56. Rahman A, Vahter M, Ekström E-C, Rahman M, Golam Mustafa AHM, Wahed MA, et al. Association of arsenic exposure during pregnancy with fetal loss and infant death: a cohort study in Bangladesh. *American Journal of Epidemiology* 2007;165:1389–1396. [PubMed: 17351293]
57. Navas-Acien A, Francesconi KA, Silbergeld EK, Guallar E. Seafood intake and urine concentrations of total arsenic, dimethylarsinate and arsenobetaine in the US population. *Environmental Research* 2011;111:110–118. [PubMed: 21093857]
58. Huhmann LB, Harvey CF, Navas-Acien A, Graziano J, Slavkovich V, Chen Y, et al. A mass-balance model to assess arsenic exposure from multiple wells in Bangladesh. *Journal of Exposure Science and Environmental Epidemiology* 2021:1–9.
59. Semmes EC, Chen J-L, Goswami R, Burt TD, Permar SR, Fouda GG. Understanding early-life adaptive immunity to guide interventions for pediatric health. *Frontiers in Immunology* 2021;11:3544.

SOCIAL MEDIA QUOTE

Do you study environmental exposures in pregnancy? The PAIR Study is a new prospective cohort examining arsenic, micronutrient deficiencies, and immune outcomes in northern Bangladesh. #epitwitter @tyler_js_smith @heaneycd

We suggest including Figure 4 in social media posts.

SYNOPSIS

Study question

The Pregnancy, Arsenic, and Immune Response (PAIR) Study was designed to assess whether arsenic exposure and micronutrient deficiencies alter maternal and newborn immunity and acute morbidity following maternal seasonal influenza vaccination during pregnancy.

What's already known

Arsenic is associated with altered immune responses and increased risk of infection, acute morbidity, and mortality. Few studies, however, have examined arsenic and immune responses in pregnancy and infancy. Of these, few have evaluated effect measure modification by micronutrient deficiencies that influence arsenic methylation.

What this study adds

The PAIR Study followed a large, representative sample of mother-infant pairs in rural northern Bangladesh. All women received the same seasonal influenza vaccine at approximately the same time during pregnancy and during the same influenza season, avoiding key confounders.




Figure 1. Map of the Pregnancy, Arsenic, and Immune Response (PAIR) Study area within the Jivita Maternal and Child Health and Nutrition Research Project in northern Bangladesh, indicating the original study area (dark grey), extensions to the study area to achieve the target sample size in the same influenza season and before the Ramadan fast (light grey), and remaining Jivita area (white). Sector boundaries are represented by light grey lines. Clinical centres where biospecimen collection was performed are noted by black circles. Major roads are indicated by black lines. The inset indicates the approximate location of the PAIR Study (black square) in Bangladesh.




Figure 2. Eligibility and enrolment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019. We conducted pregnancy surveillance from July 2018 to February 2019 and enrolled eligible pregnant women from October 2018 to March 2019. ^aInitially, pregnant women were eligible at 13–14 weeks of gestational age (GW). In November 2018, we expanded eligibility to 13–16 GW.




Figure 3. Tube well water arsenic (wAs) and urinary inorganic, monomethyl (MMA), and dimethyl (DMA) arsenic, and their sum (Σ uAs), plotted on a common log scale, among pregnant women at enrolment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019.




Figure 4.

Tube well water arsenic (wAs) and the sum of urinary inorganic, monomethyl, and dimethyl arsenic (ΣuAs), plotted on a common log scale, among pregnant women at enrolment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019. A locally estimated scatterplot smoother (LOESS) is shown by the solid line. wAs standards for the World Health Organization (10 $\mu\text{g/L}$) and Bangladesh (50 $\mu\text{g/L}$) are indicated by dashed vertical lines. wAs categories emphasize the distribution of wAs values by WHO and Bangladesh standards and indicate the sample minimum (0.014 $\mu\text{g/L}$) and maximum (615 $\mu\text{g/L}$).

Table 1.

Sociodemographic characteristics [n (%)] of pregnant women in the study area by enrolment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019.

	Enrolled (n=784)	Not Enrolled ^a (n=1,519)
Age (years) ^b		
<20	89 (11.4)	175 (11.5)
20 to 29	499 (63.6)	859 (56.6)
30	194 (24.7)	479 (31.5)
Missing	2 (0.3)	6 (0.4)
Maternal Education		
None	92 (11.7)	212 (14.0)
Class 1 to 9	548 (69.9)	1,065 (70.1)
Class 10	144 (18.4)	240 (15.8)
Missing	0 (0)	2 (0.1)
Living Standards Index		
<Median	360 (45.9)	792 (52.1)
Median	424 (54.1)	727 (47.9)
Household Size (people)		
2 to 3	307 (39.2)	518 (34.1)
4 to 5	336 (42.9)	720 (47.4%)
6	139 (17.7)	277 (18.2)
Missing	2 (0.3)	4 (0.3)
House Size (rooms) ^c		
0 to 1	366 (46.7)	721 (47.5)
2 to 3	367 (46.8)	699 (46.0)
4	51 (6.5)	98 (6.5)
Missing	0 (0)	1 (0.1)
Drinking Water Source		
Tube Well	779 (99.4)	1,516 (99.8)
Other	5 (0.6)	3 (0.2)

Notes:

^a The table does not include non-enrolled women who did not complete a separate visit to assess sociodemographic characteristics (n=313).

^b Age as of July 2018 (start of pregnancy surveillance).

^c Number of rooms excluding kitchen and storerooms.

Visits and measurements collected in women in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019.

Table 2.

	Pregnancy Visits (Gestational Weeks)							Postpartum Visits (Postpartum Months)			Both (Weekly) ^b	
Median Week/Month	14	18	22	26	30	32	34	38	<1 ^a	1	2	3
Biological Specimens												
Serum	X	X						X	X			X
Plasma	X	X						X	X			X
Peripheral blood mononuclear cells	X	X						X	X			X
Urine	X	X			X			X	X			X
Oral fluid	X	X	X	X	X		X	X	X	X	X	X
Nasal swab												X ^c
Environmental Specimens												
Tube well water	X	X						X				X
Anthropometry												
Weight	X	X			X					X		X
Height	X											X
Mid-upper arm circumference	X				X					X		X
Triceps skinfold	X											X
Subscapular skinfold	X											X
Vitals												
Blood pressure	X	X						X				X
Body temperature	X	X						X				X
Haemoglobin	X	X						X				X
Blood typing	X											
Questionnaires												
Intentionality of pregnancy												X

	Pregnancy Visits (Gestational Weeks)			Postpartum Visits (Postpartum Months)			Both (Weekly) ^b
7- or 30-day morbidity ^b	X	X	X	X	X	X	X
7-day food frequency	X					X	
Rice and water consumption	X	X		X		X	
Mental health	X		X			X	
7-day strenuous work activity	X		X			X	
Pesticide exposure history	X					X	
Poultry handling and exposure	X					X	
Handwashing and latrine use	X					X	
Tobacco use and exposure	X		X			X	
Medical history	X						
Vaccination history	X						
Household food security	X					X	
Tube well usage	X	X				X	
Altered food consumption			X				
Planned location of delivery			X				
Date and time of birth				X			
Labour and delivery				X			
Micronutrient supplements					X		
Health crisis events					X		
Resumption of menstruation						X	
Vaccination since enrolment						X	

Notes: If a pregnancy ended before all pregnancy visits were completed, the woman did not complete the remaining pregnancy visits.

^aMeasurements at <1 month postpartum were collected at a birth assessment visit (median day postpartum = 4) and a second visit <1 month postpartum (median day postpartum = 8).

^bSeven-day morbidity was collected using weekly telephone surveillance from enrolment to three months postpartum and at in-person visits. All other measurements were taken at in-person visits only.

^cA nasal swab was collected if symptoms defining influenza-like illness were reported during weekly telephone surveillance. Given limited field capacity, cases were prioritized for specimen collection based on symptom count.

Table 3.

Visits and measurements collected in infants in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019.

Median Month	Postpartum Visits (Postpartum Months)				
	<1 ^a	1	2	3	Weekly ^b
Biological Samples					
Serum	X			X	
Oral fluid		X	X	X	
Nasal swab					X ^c
Anthropometry					
Weight	X	X		X	
Length	X	X		X	
Mid-upper arm circumference	X	X		X	
Chest circumference	X	X		X	
Head circumference	X	X		X	
Vitals					
Body temperature	X			X	
Haemoglobin				X	
Blood typing				X	
Questionnaires					
Date and time of birth	X				
Birth outcome	X				
Condition of infant at birth	X				
Newborn care practices	X				
7-day morbidity ^b	X	X	X	X	X
Morbidities in first 28 days		X			
Breast feeding practices		X		X	
Early feeding		X			
Injury and bleeding		X			
Two-month morbidity	X				
Child's diet	X				
Immunization history				X	
Vitamin A supplementation				X	
Bleeding disorders				X	
Hospitalization history				X	
Recent medication				X	

Notes:

^aMeasurements at <1 month postpartum were collected at a birth assessment visit (median day postpartum = 4) and a second visit <1 month postpartum (median day postpartum = 8).

^bSeven-day morbidity was collected using weekly telephone surveillance from enrolment to three months postpartum and at in-person visits. All other measurements were taken at in-person visits only.

^cA nasal swab was collected if symptoms defining influenza-like illness were reported during weekly telephone surveillance. Given limited field capacity, cases were prioritized for specimen collection based on symptom count.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 4.

Characteristics [n (%)] of pregnant women at enrolment in the Pregnancy, Arsenic, and Immune Response (PAIR) Study, Gaibandha District, Bangladesh, 2018–2019, by completion of major study visits.

	Enrolment	28 Days Post-vaccination	<1 Month Postpartum	Three Months Postpartum
Completed	784 (100)	744 (94.9)	598 (76.3)	551 (70.3)
Maternal Age (years)^a				
<20	77 (9.8)	73 (9.8)	61 (10.2)	53 (9.6)
20 to 29	488 (62.2)	464 (62.4)	375 (62.7)	345 (62.6)
30	217 (27.7)	205 (27.6)	160 (26.8)	151 (27.4)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
Gestational Age (weeks)				
11 to 13	306 (39.0)	284 (38.2)	227 (38.0)	204 (37.0)
14	250 (31.9)	242 (32.5)	198 (33.1)	186 (33.8)
15	104 (13.3)	101 (13.6)	80 (13.4)	73 (13.2)
16 to 17	124 (15.8)	117 (15.7)	93 (15.6)	88 (16.0)
Parity				
Nulliparous	140 (17.9)	136 (18.3)	107 (17.9)	90 (16.3)
Primiparous	364 (46.4)	340 (45.7)	278 (46.5)	262 (47.6)
Multiparous	280 (35.7)	268 (36.0)	213 (35.6)	199 (36.1)
Maternal Education				
None	92 (11.7)	89 (12.0)	60 (10.0)	57 (10.3)
Class 1 to 9	548 (69.9)	521 (70.0)	431 (72.1)	396 (71.9)
Class 10	144 (18.4)	134 (18.0)	107 (17.9)	98 (17.8)
Living Standards Index				
<Median	392 (50.0)	370 (49.7)	294 (49.2)	272 (49.4)
Median	392 (50.0)	374 (50.3)	304 (50.8)	279 (50.6)
Household Size (people)				
2 to 3	307 (39.2)	289 (38.8)	224 (37.5)	207 (37.6)
4 to 5	336 (42.9)	321 (43.1)	259 (43.3)	238 (43.2)
6	139 (17.7)	132 (17.7)	113 (18.9)	104 (18.9)
Missing	2 (0.3)	2 (0.3)	2 (0.3)	2 (0.4)
House Size (rooms)				
0 to 1	366 (46.7)	342 (46.0)	268 (44.8)	248 (45.0)
2 to 3	367 (46.8)	353 (47.4)	294 (49.2)	270 (49.0)
4	51 (6.5)	49 (6.6)	36 (6.0)	33 (6.0)
Height (cm)				
Mean (SD)	150 (5.20)	150 (5.19)	150 (5.17)	150 (5.19)

	Enrolment	28 Days Post-vaccination	<1 Month Postpartum	Three Months Postpartum
Body Mass Index (kg/m ²)				
Mean (SD)	21.9 (3.44)	22.0 (3.41)	21.9 (3.36)	22.0 (3.36)
Urine Arsenic (uAs) (µg/L) ^b				
Tertile 1 (2.98 to 22.5)	261 (33.3)	250 (33.6)	203 (33.9)	189 (34.3)
Tertile 2 (22.5 to 45.6)	261 (33.3)	248 (33.3)	193 (32.3)	175 (31.8)
Tertile 3 (46.3 to 451)	261 (33.3)	245 (32.9)	201 (33.6)	186 (33.8)
Missing	1 (0.1)	1 (0.1)	1 (0.2)	1 (0.2)

Notes:

^a Age at enrolment.

^b Urinary arsenic is the sum of inorganic and methylated arsenic species.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript